KIES PETER 4
4 · INOVIO PHARMACEUTICALS, INC. · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
INOVIO (INO) CFO Peter Kies Receives Award via RSU Vesting
What Happened
Peter Kies, Chief Financial Officer of INOVIO Pharmaceuticals (INO), had restricted stock units (RSUs) vest on February 26, 2026. A total of 15,644 RSUs converted into common shares (5,010 from a 2024 grant and 10,634 from a 2025 grant). To satisfy tax withholding obligations, the company withheld 9,259 of those shares (treated as dispositions) at $1.79 per share for a tax withholding value of about $16,573, leaving 6,385 shares delivered to Kies.
Key Details
- Transaction date: February 26, 2026; Form 4 filed February 27, 2026 (timely).
- Shares vested/converted: 15,644 total (5,010 + 10,634).
- Shares withheld for taxes: 9,259 shares at $1.79/share; withholding value ≈ $16,573 (reported as disposals).
- Net shares issued to Kies: 6,385 shares.
- Transaction codes: M = exercise/conversion of RSUs; F = shares withheld to satisfy tax obligations.
- Shares owned after transaction: not specified in the provided filing.
- Footnotes: vesting schedules from grants on Feb 28, 2024 (5,010 vested in 2026) and Feb 27, 2025 (10,634 vested in 2026). Vested RSUs may be settled in shares, cash, or both.
Context
This was a routine RSU vesting and tax-withholding event, not an open-market sale or purchase. The withholding of shares to cover taxes is common and does not, by itself, indicate a change in insider sentiment. The filing appears timely (filed the business day after the vesting date).
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-26+5,010→ 35,267 total - Tax Payment
Common Stock
[F2]2026-02-26$1.79/sh−2,965$5,307→ 32,302 total - Exercise/Conversion
Common Stock
[F3]2026-02-26+10,634→ 42,936 total - Tax Payment
Common Stock
[F4]2026-02-26$1.79/sh−6,294$11,266→ 36,642 total - Exercise/Conversion
Restricted Stock Unit
[F1]2026-02-26−5,010→ 5,009 total→ Common Stock (5,010 underlying) - Exercise/Conversion
Restricted Stock Unit
[F3]2026-02-26−10,634→ 21,266 total→ Common Stock (10,634 underlying)
- 375(indirect: By Spouse)
Common Stock
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 was as follows: 5,010 shares vested on February 26, 2025; 5,010 shares vested on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
- [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
- [F3]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 31,900 restricted stock units granted on February 27, 2025 was as follows: 10,634 shares vested on February 26, 2026; 10,633 shares will vest on February 26, 2027; 10,633 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
- [F4]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (3) herein.